[Corrections] Correction to Lancet Oncol 2021; 22: 620–31

Poveda A, Floquet A, Ledermann JA, et al. Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol 2021; 22: 620–31—The appendix of this Article has been corrected as of June 24, 2024.